Albumedix, now part of Sartorius, is a science-driven company and recognized leader of best-in-class albumin-enabled solutions. Established in the UK in 1984, with a mission to empower excellence, Albumedix has supported its life-science partners to deliver hundreds of million safe doses of clinical and marketed therapeutics, globally. Albumedix’ solutions include the world’s only USP-NF compliant recombinant human albumin (Recombumin®), client-centric development and compliance services and drug-enhancing technologies (Veltis®). By always striving for more and collaboratively challenging status quo, Albumedix enables the development and commercialisation of advanced therapies and next-generation biopharmaceuticals to the benefit of people worldwide.